ICUI

SEC source: 0001410442-24-000007 · edgardoc.xml · nonDerivative · entry 4

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,832

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.275 to $173.175, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000007 · edgardoc.xml · nonDerivative · entry 3

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,218

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.25 to $172.23, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000007 · edgardoc.xml · nonDerivative · entry 2

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,365

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.28 to $171.23, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000007 · edgardoc.xml · nonDerivative · entry 1

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,593

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000006 · edgardoc.xml · derivative · entry 7

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,373

Underlying: Common Stock · 12,000 shares

Expires 2025-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000006 · edgardoc.xml · nonDerivative · entry 5

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,593

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.08 to $180.54, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000006 · edgardoc.xml · nonDerivative · entry 4

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,381

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.975 to $179.69, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000006 · edgardoc.xml · nonDerivative · entry 3

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,756

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.96 to $178.88, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000006 · edgardoc.xml · nonDerivative · entry 2

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,437

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.92 to $177.88, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000006 · edgardoc.xml · nonDerivative · entry 1

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,593

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000005 · edgardoc.xml · derivative · entry 10

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,373

Underlying: Common Stock · 3,805 shares

Expires 2025-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000005 · edgardoc.xml · derivative · entry 9

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,178

Underlying: Common Stock · 4,440 shares

Expires 2025-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000005 · edgardoc.xml · derivative · entry 8

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,618

Underlying: Common Stock · 3,755 shares

Expires 2025-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000005 · edgardoc.xml · nonDerivative · entry 6

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,593

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.00 to $164.5, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000005 · edgardoc.xml · nonDerivative · entry 5

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,398

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000005 · edgardoc.xml · nonDerivative · entry 4

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,593

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.99 to $163.96, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000005 · edgardoc.xml · nonDerivative · entry 3

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,033

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000005 · edgardoc.xml · nonDerivative · entry 2

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,593

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.98 to $162.94, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001410442-24-000005 · edgardoc.xml · nonDerivative · entry 1

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001698998-24-000004 · edgardoc.xml · nonDerivative · entry 1

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,107

F1 · price: The sales price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.00 to $163.825, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full

SEC source: 0001410442-24-000004 · edgardoc.xml · derivative · entry 4

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,373

Underlying: Common Stock · 12,000 shares

Expires 2025-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001410442-24-000004 · edgardoc.xml · nonDerivative · entry 2

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,593

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

F3 · price: All shares sold were sold at the exact price disclosed.

SEC source: 0001410442-24-000004 · edgardoc.xml · nonDerivative · entry 1

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,593

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.

SEC source: 0001669639-24-000003 · edgardoc.xml · nonDerivative · entry 1

Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,482

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.48 to $145.00, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001727477-24-000004 · edgardoc.xml · nonDerivative · entry 2

Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.28 to $104.60, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001727477-24-000004 · edgardoc.xml · nonDerivative · entry 1

Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,032

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.28 to $104.27, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0000950170-24-061285 · ownership.xml · nonDerivative · entry 1

FINNEY ELISHA W · CIK 0001217439 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,129

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.9472 to $104.9478, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0000950170-24-060659 · ownership.xml · derivative · entry 3

Hoffmeister David F · CIK 0001305975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 948 shares

Expires 2024-05-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award or the following annual stockholder meeting, whichever occurs first.

SEC source: 0000950170-24-060659 · ownership.xml · derivative · entry 2

Hoffmeister David F · CIK 0001305975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,723 shares

Expires 2025-05-15

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award or the following annual stockholder meeting, whichever occurs first.

SEC source: 0000950170-24-060659 · ownership.xml · nonDerivative · entry 1

Hoffmeister David F · CIK 0001305975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F2 · price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

SEC source: 0000950170-24-060657 · ownership.xml · derivative · entry 3

KENNEDY KOLLEEN T · CIK 0001531738 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 948 shares

Expires 2024-05-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award or the following annual stockholder meeting, whichever occurs first.

SEC source: 0000950170-24-060657 · ownership.xml · derivative · entry 2

KENNEDY KOLLEEN T · CIK 0001531738 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,723 shares

Expires 2025-05-15

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award or the following annual stockholder meeting, whichever occurs first.

SEC source: 0000950170-24-060657 · ownership.xml · nonDerivative · entry 1

KENNEDY KOLLEEN T · CIK 0001531738 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,562

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F2 · price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

SEC source: 0000950170-24-060654 · ownership.xml · derivative · entry 3

Abbey Donald · CIK 0001534342 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 948 shares

Expires 2024-05-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award or the following annual stockholder meeting, whichever occurs first.

SEC source: 0000950170-24-060654 · ownership.xml · derivative · entry 2

Abbey Donald · CIK 0001534342 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,723 shares

Expires 2025-05-15

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award or the following annual stockholder meeting, whichever occurs first.

SEC source: 0000950170-24-060654 · ownership.xml · nonDerivative · entry 1

Abbey Donald · CIK 0001534342 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F2 · price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

SEC source: 0000950170-24-060650 · ownership.xml · derivative · entry 3

FINNEY ELISHA W · CIK 0001217439 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 948 shares

Expires 2024-05-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award or the following annual stockholder meeting, whichever occurs first.

SEC source: 0000950170-24-060650 · ownership.xml · derivative · entry 2

FINNEY ELISHA W · CIK 0001217439 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,723 shares

Expires 2025-05-15

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: These Restricted Stock Units vest on the anniversary of the date of the award or the following annual stockholder meeting, whichever occurs first.

SEC source: 0000950170-24-060650 · ownership.xml · nonDerivative · entry 1

FINNEY ELISHA W · CIK 0001217439 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,429

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F2 · price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

SEC source: 0001645866-24-000001 · edgardoc.xml · derivative · entry 4

Greenberg David C. · CIK 0001645866 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,723

Underlying: Common Stock · 1,723 shares

Expires 2025-05-15

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F2 · price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

SEC source: 0001645866-24-000001 · edgardoc.xml · derivative · entry 3

Greenberg David C. · CIK 0001645866 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 948 shares

Expires 2024-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

SEC source: 0001645866-24-000001 · edgardoc.xml · nonDerivative · entry 1

Greenberg David C. · CIK 0001645866 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,037

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

SEC source: 0001871884-24-000001 · edgardoc.xml · derivative · entry 3

Hernandez Laurie · CIK 0001871884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,723

Underlying: Common Stock · 1,723 shares

Expires 2025-05-15

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F2 · price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

SEC source: 0001871884-24-000001 · edgardoc.xml · derivative · entry 2

Hernandez Laurie · CIK 0001871884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 948 shares

Expires 2024-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

SEC source: 0001871884-24-000001 · edgardoc.xml · nonDerivative · entry 1

Hernandez Laurie · CIK 0001871884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,885

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

SEC source: 0002013412-24-000005 · edgardoc.xml · nonDerivative · entry 1

Sousa Ben · CIK 0002013412 · Chief Information Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,319

F1 · price: All shares sold were sold at the exact price disclosed.

SEC source: 0001698998-24-000002 · edgardoc.xml · nonDerivative · entry 1

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,980

F1 · price: All shares sold were sold at the exact price disclosed.

SEC source: 0001727477-24-000003 · edgardoc.xml · derivative · entry 3

Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,496

Underlying: Common Stock · 3,247 shares

Expires 2026-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. These awards were legally granted on March 15, 2023 but were subject to shareholder approval on May 17, 2023.

SEC source: 0001727477-24-000003 · edgardoc.xml · nonDerivative · entry 2

Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,539

SEC source: 0001727477-24-000003 · edgardoc.xml · nonDerivative · entry 1

Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,319

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.